<DOC>
	<DOCNO>NCT02608125</DOCNO>
	<brief_summary>This multi-center , open label , non-randomized Phase 1 study , conduct two part , Part A , Part B . Part A dose escalation phase evaluate safety tolerability profile PRN1371 , FGFR 1-4 Kinase inhibitor . Part B Cohort Expansion phase evaluate safety tolerability , preliminary activity , PK , PD patient FGFR genetic alteration .</brief_summary>
	<brief_title>A Dose Escalation Dose Expansion Study PRN1371 Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The study dose escalation study . The protocol specifies rule dose-limiting toxicity maximum tolerate dose ( MTD ) . To gain experience MTD , and/or low optimal biologic dose level , expansion cohort 20 patient , enrich solid tumor fibroblast growth factor receptor ( FGFR ) 1 , 2 , 3 4 genetic alteration .</detailed_description>
	<criteria>Age ≥ 18 year Histological cytological documentation advance solid tumor Subject must metastatic recurrent disease fail firstline systemic treatment , indicate , fail approve secondline therapy , standard therapy option anticipate result durable remission Subject must evaluable , progressive , measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) guideline , Version 1.1 Adequate bone marrow , liver , renal function Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 For Part B subject : The patient 's tumor evaluate prospectively identify FGFR 1 , 2 , 3 , 4 genetic alteration . Patients receive adequate prior treatment highly selective FGFR inhibitor Patients major uncontrolled medical condition , e.g. , recent myocardial infarction , stroke , diabetes , active hepatitis Patients receive prior systemic anticancer therapy ≤ 3 week prior study start ( 6 week nitrosourea , antibody , mitomycinC ) Patients diagnose another primary malignancy within 3 year prior study start , exception adequately treat basal cell carcinoma , squamous cell carcinoma , nonmelanomatous skin cancer , carcinoma situ uterine cervix Patients glioblastoma multiforme Patient primary neoplasm brain know uncontrolled metastasis central nervous system ( CNS ) . Patients brain metastasis eligible , provide show clinical radiographically stable disease least 4 week definitive therapy use steroid least 4 week prior first dose PRN1371 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>FGFR</keyword>
</DOC>